15. Aleem, F. A. (1985). Menopausal syndrome: Plasma levels of betaendorphin in postmenopausal women measured by a specific radioimmunoassay. Maturitas, 7, 329–334; Genazzani, A. R., et al. (1988). Steroid replacement treatment increases beta-endorphin and beta-lipotropin plasma levels in postmenopausal women. Gynecol Obstet Invest, 26, 153–159.
16. Roca, C. A., et al. (1999). Gonadal steroids and affective illness. Neuroscientist, 5 (4), 227–237; Halbreich, U. (1997). Role of estrogen in postmenopausal depression. Neurology, 48 (5, suppl. 7), S16–S20.
17. Garcia-Segura, L. M., et al. (1996). Effect of sex steroids on brain cells. In B. G. Wren (ed.), Progress in the Management of the Menopause. The Proceedings of the 9th International Congress on the Menopause, Sydney, Australia, 278–285. New York: Parthenon Publishing.
18. Smoller, J. W., et al. (2009). Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the women’s health initiative study. Arch Intern Med, 169, 2128–2139.
19. Turner, E. H., et al. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med, 358, 252–260.
20. Fournier, J. C., et al. (2010). Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA, 303, 47–53.
21. Pert, C. B. (Oct. 20, 1997). Letter to the editor. Time, 150 (16).
22. Doogan, D. P., & Caillard, V. (1992). Sertraline in the prevention of depression. Br J Psychiatry, 160, 217–222; Eric, L. (1991). A prospective, doubleblind, comparative, multicenter study of paroxitine and placebo preventing recurrent major depressive episodes. Biol Psychiatry, 29 (suppl. 1), 254S–255S.
23. Young, R. J. (1979). Effect of regular exercise on cognitive functioning and personality. Br J Sports Med, 13 (3), 110–117; Gutin, B. (1966). Effect of increase in physical fitness on mental ability following physical and mental stress. Res Q, 37 (2), 211–220.
24. Hamer, M., Stamatakis, E., & Steptoe, A. (2009). Dose response relationship between physical activity and mental health: The Scottish Health Survey. Br J Sports Med, 43, 14, 1111–1114.
25. Lesperance, F., et al. (2009). The efficacy of eicosapentaenoic acid for major depression: Results of the OMEGA-3D trial, 9th World Congress of Biological Psychiatry, Abstract FC-25-005. Presented July 1, 2009, in Paris, France; available at http://www.wfsbp-congress.org/fileadmin/user_upload/WFSBP_Final_Programme_090625.pdf.
26. Coppen, A. (1967). The biochemistry of affective disorders. Br J Psychiatry, 113, 1237–1264; Stewart, J. W., et al. (1984). Low B6 levels in depressed outpatients. Biol Psychiatry, 19 (4), 613–616; Hall, R. C. W., & Joffe, J. R. (1973). Hypomagnesemia: Physical and psychiatric symptoms. JAMA, 224 (13), 1749–1751; Lieb, J., Karmali, R., & Horrobin, D. (1983). Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med, 10 (4), 361–367.
27. Fux, M., Levine, J., Aviv, A., & Belmaker, R. H. (1996). Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry, 153 (9), 1219–1221; Levine, J., et al. (1995). Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry, 152, 792–794.
28. DeVenna, M., & Rigamoni, R. (1992). Oral S-adenosyl-L-methionine in depression. Curr Ther Res, 52, 478–485; Di Benedetto, P., et al. (1993). Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia. Curr Ther Res, 53, 222–229; Muskin, P. R., ed. (2000). Complementary and Alternative Medicine and Psychiatry (Review of Psychiatry). (Vol. 19, 8–18). Washington, D.C.: American Psychiatric Association Press; Shehin, V. O., et al. (1990). SAM-e in adult ADHD. Psychopharmacol Bull, 25, 249–253.
29. Greendale, G. A., et al. (2009). Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology, 72, 1850–1857.
30. Gould, E., et al. (1999). Learning enhances adult neurogenesis in the hippocampal formation. Nature Neurosci, 2, 260–265.
31. Evans, P. H. (1991). Cephaloconiosis: A free radical perspective on the proposed particulate-induced etiopathogenesis of Alzheimer’s dementia and related disorders. Med Hypotheses, 34 (3), 209–219.
32. Freedman, M., et al. (1984). Computerized axial tomography in aging. In M. L. L. Albert (ed.), Clinical Neurology of Aging. New York: Oxford University Press; Lehr, J., & Schmitz-Scherzer, R. (1976). Survivors and nonsurvivors: Two fundamental patterns of aging. In H. Thomae (ed.), Patterns of Aging: Findings from the Bonn Longitudinal Study of Aging. Basel: S. Karger; Benton, M. L., et al. (1981). Normative observations on neuropsychological test performance in old age. J Clin Neuropsychiatry, 3, 33–42.
33. Boyle, P. A., et al. (2010). Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. Arch Gen Psychiatry, 67 (3), 304–310.
34. De Meyer, G., et al. (2010). Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol, 67, 949–956.
35. Alzheimer’s Association (2010). 2010 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 6; also available at www.alz.org/documents_custom/report_alzfactsfigures2010.pdf.
36. Plassman, B. L., et al. (2007). Prevalence of dementia in the United States: The aging, demographics and memory study. Neuroepidemiology, 29, 125–132.
37. Nash, J. M. (July 24, 2000). The new science of Alzheimer’s. Time, 156 (4), 51.
38. Snowdon, D., et al. (1996). Linguistic ability in early life and cognitive function and Alzheimer’s disease in late life: Findings from the Nun Study. JAMA, 275 (7), 528–532; Snowdon, D., et al. (1997). Brain infarction and the clinical expression of Alzheimer’s disease: The Nun Study. JAMA, 277 (10), 813–817.
39. Wilson, R. S., et al. (2010). Cognitive activity and the cognitive morbidity of Alzheimer disease. Neurology, 75, 990–996.
40. Jefferson, A. L. (2010). Cardiac index is associated with brain aging: The Framingham heart study. Circulation, 122, 690–697; Jefferson, A. L. (2010). Cardiac output as a potential risk factor for abnormal brain aging. Journal of Alzheimer’s Disease, 20, 813–821.
41. Baldereschi, M., et al. (1998). Estrogen replacement therapy and Alzheimer’s disease in the Italian Longitudinal Study on Aging. Neurology, 50, 996–1002; Kawas, C., et al. (1997). A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: The Baltimore Longitudinal Study of Aging. Neurology, 48, 1517–1521; Paganini-Hill, A., & Henderson, V. W. (1996). Estrogen replacement therapy and risk of Alzheimer’s disease. Arch Intern Med, 156 (19), 2213–2217; Tang, M. X., et al. (1996). Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet, 358, 429–432; Ohkura, V., et al. (1994). Evaluation of estrogen treatment in female patients with dementia of Alzheimer’s type. Endocrinol J, 41, 361–371; Henderson, V., et al. (1994). Estrogen replacement therapy in older women: Comparisons between Alzheimer’s disease cases and nondemented control subjects. Arch Neurol, 51, 896–900; Paganini-Hill, A., et al. (1994). Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol, 140, 256–261; Brenner, D. E., et al. (1994). Postmenopausal estrogen replacement therapy on the risk of Alzheimer’s disease: A population-based case control study. Am J Epidemiol, 140, 262–267; Honjo, H., et al. (1993). An effect of conjugated estrogen to cognitive impairment in women with senile dementia, Alzheimer’s type: A placebo-controlled double-blind study. J Jpn Menopause Soc, 1, 167–171; Kantor, H., et al. (1973). Estrogen for older women. Am J Obstet Gynecol, 116, 115–118; Caldwell, B. M. (1954). An evaluation of psychological effects of sex hormone administration in aged women. J Gerontol, 9, 168–174.
42. McEwen, B. S., et al. (1999). Inhibition of dendritic spine induction on hippocampal ca-1 pyramidal neurons by nonsteroidal estrogen antagonists in female rats. Endocrinology, 140, 1044–1047.
43. Manly, J. J., et al. (2000). Endogenous estrogen levels and Alzheimer’s disease among postmenopausal women. Neurology, 54, 833–83
7.
44. Baldereschi, M., et al. (1998). Op. cit.; Schneider, L. S., et al. (1996). Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology, 46, 1580–1584; Brinton, R. D., et al. (1997). 17-beta-estradiol increases the growth and survival of cultured cortical neurons. Neurochem Res, 22, 1339–1351; Brinton, R. D., et al. (1997). Equilin, a principal component of the estrogen replacement therapy Premarin, increases the growth of cortical neurons via an NMDA receptordependent mechanism. Exp Neurol, 147, 211–220; Matsumoto, A., et al. (1985). Estrogen stimulates neuronal plasticity in the deafferented hypothalamic arculate nucleus in aged female rats. Neurosci Res, 2, 412–418; Okhura, T., et al. (1995). Estrogen increases cerebral and cerebellar blood flow in postmenopausal women. Menopause, 2, 13–18; Singh, M., et al. (1994). Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res, 644, 305–312; Singh, M., et al. (1996). The effect of ovariectomy and estradiol replacement on brain derived neurotrophic factor messenger hippocampal brain expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology, 136, 2320–2324.
45. Rivera, C. M., et al. (2009). Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology, 33, 32–40.
46. Sherwin, B. (1997). Estrogen effects of cognition in menopausal women. Neurology, 48 (suppl. 7), S21–S26.
47. McEwen, B. S., & Wooley, C. S. (1994). Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol, 29, 431–436; Wooley, C. S., & McEwen, B. S. (1993). Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol, 336, 293–306.
48. Loucks, T. L., & Berga, S. L. (2009). Does postmenopausal estrogen use confer neuroprotection? Semin Reprod Med, 27, 260–274.
49. McLaughlin, I. J., et al. (1990). Zinc in depressive disorder. Acta Psychiatr Scand, 82, 451–453.
50. Shaw, D. M., et al. (1988). Senile dementia and nutrition [letter]. BMJ, 288, 792–793.
51. Gibson, Q. E., et al. (1988). Reduced activities of thiamine dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol, 45, 836–840.
52. Strachan, R. N., & Henderson, J. G. (1967). Dementia and folate deficiency. Q J Med, 36, 189–204; Perkins. A. J., et al. (1999). Association of antioxidants and memory in multiethnic elderly sample using the Third National Health and Nutrition Examination Study. Am J Epidemiol, 150, 37–44.
53. Knekt, P., et al. (2010). Serum vitamin D and the risk of Parkinson disease. Arch Neurol, 67, 808–811.
54. Rovio, S., et al. (2005). Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol, 4 (11), 705–711.
55. Erickson, K. I., & Kramer, A. F. (2009). Aerobic exercise effects on cognitive and neural plasticity in older adults. Br J Sports Med, 43, 22–24; Liu-Ambrose, T., et al. (2008). Otago home-based strength and balance retraining improves executive functioning in older fallers: A randomized controlled trial. J Am Geriatr Soc, 56, 1821–1830; M. Angevaren et al. (July 16, 2008). Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database of System Reviews, 2, CD005381.
56. Petrovitch, H., & White, L. (2005). Exercise and cognitive function. Lancet Neurol, 4 (11), 690–691.
57. Hoffman and Herbert (1990). Beware of cold remedies in the elderly. Courtlandt Forum, 28–41.
58. Lim, S. Y., & Suzuki, H. (2000). Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr, 130 (6), 1629–1632; Gamoh, S., et al. (1999). Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience, 93 (1), 237–241; Calon, F., et al. (2004). Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron, 43 (5), 633–645.
59. Kalmijn, S., et al. (2004). Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology, 62 (2), 275–280.
60. He, F. J., et al. (2006). Fruit and vegetable consumption and stroke: Metaanalysis of cohort studies. Lancet, 367, 320–326.
61. Pan, Y., et al. (2000). Soy phytoestrogens improve radial arm maze performance in ovariectomized retired breeder rats and do not attenuate benefits of 17-beta-estradiol treatment. Menopause, 7 (4), 230–235; Kim, H., et al. (2000). Attenuation of neurodegeneration-relevant modifications of brain proteins by dietary soy. Biofactors, 12 (1–4), 243–250. Review.
62. Pan, Y., et al. (1999). Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats. Proc Soc Exp Biol Med, 221 (2), 118–125.
63. Zeng, H., Chen, Q., & Zhao, B. (2004). Genistein ameliorates betaamyloid peptide (25–35)-induced hippocampal neuronal apoptosis. Free Radic Biol Med, 36 (2), 180–188; Sonee, M., Sum, T., Wang, C., &Mukherjee, S. K. (2004). The soy isoflavone, genistein, protects human cortical neuronal cells from oxidative stress. Neurotoxicology, 25 (5), 885–891.
64. File, S. E., et al. (2001). Eating soya improves human memory. Psychopharmacology (Berl), 157 (4), 430–436.
65. File, S. E., et al. (2005). Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function. Menopause, 12 (2), 193–201.
66. Kritz-Silverstein, D., Von Muhlen, D., Barrett-Connor, E., & Bressel, M. A. (2003). Isoflavones and cognitive function in older women: The Soy and Postmenopausal Health In Aging (SOPHIA) Study. Menopause, 10 (3), 196–202.
67. Refat, S. L., et al. (1990). Effect of exposure of miners to aluminum powder. Lancet, 336, 1162–1165.
68. Council on Scientific Affairs (1985). Aspartame: Review on safety issues. JAMA, 254 (3), 400–402; U.S. Department of Health and Human Services (1980). Decision of the Public Board of Inquiry (DHHS docket 75F–0335). Rockville, MD: Food & Drug Administration; Wurtman, R. J. (1983). Neurochemical changes following high-dose aspartame with dietary carbohydrates. N Engl J Med, 309, 429–430; Yokogoshi, H., et al. (1984). Effects of aspartame and glucose administration on brain and plasma levels of large neutral amino acids and brain 5-hydroxyindoles. Am J Clin Nutr, 40 (1), 1–7; Aspartame Consumer Safety Network, P.O. Box 780634, Dallas, TX 75378. Tel: 214–352–4268.
69. McEwen, B. S., et al. (1999). Op. cit.
70. Levy, B. R., Slade, M. D., Kunkel, S. R., & Kasl, S. V. (2002). Longevity increased by positive self-perceptions of aging. J Pers Soc Psychol, 83 (2), 261–270.
71. Connor, J. R., Melone, J. H., & Yuen, A. R. (1981). Dendritic length in aged rats’ occipital cortex: An environmentally induced response. Experimental Neurology, 73 (3), 827–830; Connor, J. R., Diamond, M. C., &Johnson, R. E. (1980). Aging and environmental influences on two types of dendritic spines in the rat occipital cortex. Exp Neurol, 70 (2), 371–379.
72. Eriksson, P., et al. (1998). Neurogenesis in the adult human hippocampus. Nature Med, 4 (11), 1313–1317.
73. Diamond, M., et al. (1985). Plasticity in the 904-day male rat cerebral cortex. Exp Neurol, 87, 309–317.
74. Yaffe, K., et al. (2010). Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry, 67, 608–613.
75. Hausdorff, J., et al. (1999). The power of ageism on physical function of older persons: Reversibility of age-related gait changes. J Am Geriatric Soc, 47, 1346–1349.
76. Langer, E. (1989). Mindfulness, 113. Reading, MA: Addison-Wesley.
Chapter 11: From Rosebud to Rose Hip
1. Fisher, G. J., et al. (1997). Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med, 337 (20), 1419–1428.
2. Mosher, C. E., & Danoff-Burg, S. (2010). Addicti
on to indoor tanning: Relation to anxiety, depression, and substance use. Arch Dermatol, 146, 412–417.
3. Cosgrove, M. C., et al. (2007). Dietary nutrient intakes and skin-aging appearance among middle-aged American women. Am J Clin Nutr, 86, 1225–1231.
4. Van Scott, E. J., & Yu, R. J. (1989). Alpha hydroxy acids: Procedures for use in clinical practice. Cutis, 43 (3), 222–228.
5. Van Scott, E. J., & Yu, R. J. (1984). Hyperkeratinization, corneocyte cohesion, and alpha hydroxy acids. J Am Acad Dermatol, 11 (5 pt. 1), 867–879; Stiller, M. J., et al. (1996). Topical 8% glycolic acid and 8% L-lactic acid creams for the treatment of photodamaged skin: A double-blind vehiclecontrolled clinical trial. Arch Dermatol, 132 (6), 631–636.
6. Steenvoorden, D. P., & van Henegouwen, G. M. (1997). The use of endogenous antioxidants to improve photoprotection. J Photochem Photobiol B, 41 (1–2), 1–10.
7. Fuchs, J., & Kern, H. (1998). Modulation of UV-light-induced skin inflammation by D-alpha-tocopherol and L-ascorbic acid: A clinical study using solar simulated radiation. Free Radic Biol Med, 25 (9), 1006–1012; Steenvoorden, D. P., & Beijersbergen van Henegouwen, G. (1999). Protection against UV-induced systemic immunosuppression in mice by a single topical application of the antioxidant vitamins C and E. Int J Radiat Biol, 75 (6), 747–755.
The Wisdom of Menopause Page 85
